Free ebooks Library zlib project

Mark Miedel

Mark Miedel, Ph.D.
Research Assistant Professor

Ph.D. Cell Biology and Physiology, University of Pittsburgh School of Medicine

Phone: 412-383-9893

Research Summary

Selective inhibition of the estrogen receptor (ER) pathway via endocrine therapy is the primary treatment option for ER-positive breast cancer. However, a major problem in the clinical treatment of ER-positive breast cancer is the development of resistance to endocrine therapies. In 20-50% of estrogen receptor-positive (ER+) metastatic breast cancer patients who underwent estrogen deprivation therapy, the expression of mutations within the ER ligand-binding domain, not evident in primary tumors, has been observed. The overall aim of my research is focused on identifying the mechanisms that cause resistance in ER ligand binding domain mutants, and to use this information to develop novel therapeutic strategies for the treatment of endocrine-resistant metastatic breast cancer.

Recent Publications
Shanhang J, Miedel MT, Ngo M, Hessenius R, Wang P, Bahreini A, Li Z, Ding Z, Chen N, Shun TY, Zuckerman DM, Taylor DL, Puhalla SL, Lee AV, Oesterreich S, Stern AM (2017) Clinically observed estrogen receptor alpha mutations within the ligand-binding domain confer distinguishable phenotypes indicative of Darwinian-like somatic evolution Oncology.

Shi S, Luke CJ, Miedel MT, Silverman GA, Kleyman TR (2016) Activation of the Caenorhabditis elegans degenerin channel by shear stress requires the MEC-10 subunit. Journal of Biological Chemistry. 291(27): 14012-22